gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with irinotecan in 1 studies
| Studies (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Trials (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Recent Studies (post-2010) (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 638 | 31 | 243 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, G; Axtell, AL; Bardeesy, N; Caravan, P; Chawla, A; Chen, YI; Deshpande, V; Erstad, DJ; Farrar, CT; Ferreira, DS; Ferrone, CR; Fuchs, BC; Ghoshal, S; Graham-O'Regan, KA; Humblet, V; Jones, C; Jordan, VC; Kontos, F; Lanuti, M; Li, S; Michelakos, T; Qadan, M; Rotile, NJ; Sojoodi, M; Tanabe, KK; Taylor, MS | 1 |
1 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and irinotecan
| Article | Year |
|---|---|
Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemoradiotherapy, Adjuvant; Collagen; Disease-Free Survival; Female; Fibrosis; Fluorouracil; Follow-Up Studies; Heterocyclic Compounds; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Mice; Middle Aged; Molecular Imaging; Molecular Probes; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organometallic Compounds; Oxaliplatin; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Xenograft Model Antitumor Assays | 2020 |